Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Jun Gong MD

Jun Gong MD

Assistant Professor, Department of Medicine, Division of Hematology and Oncology, Cedars-Sinai Medical Center, Los Angeles, California

Jun Gong, MD, is an Assistant Professor in the Department of Medicine, Division of Hematology and Oncology at Cedars-Sinai Medical Center. As a medical oncologist, his primary clinical interests are in gastrointestinal (GI), hepatobiliary, and genitourinary (GU) cancers with a multidisciplinary focus of care along with colleagues from surgery, gastroenterology, radiation oncology, radiology, and urology. Dr. Gong is focused on translational and clinical cancer research with interests in early therapeutic trials (immunotherapy, targeted therapies, biologics, and other systemic therapies) and biomarker development to improve patient outcomes in GI and GU cancers. 

Disclosures

Consultant or Advisory Role – EMD Serono, Elsevier, Exelixis, QED Therapeutics, Natera, Basilea, HalioDx, Eisai, Janssen, Astellas, Amgen, Pfizer, Seagen, and Bayer.

Recent Contributions to PracticeUpdate:

  1. Telaglenastat Plus Cabozantinib or Everolimus for Advanced or mRCC
  2. Exploring Deubiquitylase OTUD6B as a Potential Therapeutic Strategy for ccRCC With VHL Mutations
  3. Genetic Determinants of Shorter Time on Active Surveillance in Metastatic RCC
  4. Radiation Necrosis in RCC Brain Metastases Treated With ICIs and Radiosurgery
  5. Prediction of Early Progression of mRCC Treated With a First-Line TKI
  6. Clinical Outcomes and Adverse Events After First-Line Treatment in Metastatic Renal Cell Carcinoma
  7. Clinical and Molecular Characterization of Translocation RCC
  8. Pembrolizumab Outperforms TKIs in Patients With High-Risk Renal Cell Carcinoma After Nephrectomy
  9. Stereotactic Radiotherapy and Short-Course Pembrolizumab for Oligometastatic Renal Cell Carcinoma
  10. Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney Cancer

Elsewhere

Recently Updated